NasdaqGS:AMGN - アナリストの将来予測と過去の財務データ ( )USD Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	34,713	6,876	13,143	13,480	24
12/31/2025	33,967	6,208	12,875	13,452	27
12/31/2024	32,998	4,109	15,699	13,764	27
3/31/2024	29,532	3,763	7,098	8,096	N/A
12/31/2023	28,190	6,717	7,359	8,471	N/A
9/30/2023	26,833	7,566	9,379	10,582	N/A
6/30/2023	26,582	7,979	9,685	10,800	N/A
3/31/2023	26,190	7,917	7,531	8,621	N/A
12/31/2022	26,323	6,552	8,785	9,721	N/A
9/30/2022	26,330	6,835	8,997	9,880	N/A
6/30/2022	26,384	6,576	8,355	9,320	N/A
3/31/2022	26,316	5,723	8,417	9,321	N/A
12/31/2021	25,979	5,893	8,381	9,261	N/A
9/30/2021	25,767	5,609	7,840	8,606	N/A
6/30/2021	25,484	5,746	8,897	9,556	N/A
3/31/2021	25,164	7,085	9,835	10,467	N/A
12/31/2020	25,424	7,264	9,889	10,497	N/A
9/30/2020	24,987	7,352	10,235	10,858	N/A
6/30/2020	24,301	7,299	10,209	10,867	N/A
3/31/2020	23,966	7,675	8,795	9,439	N/A
12/31/2019	23,362	7,842	8,532	9,150	N/A
9/30/2019	23,395	8,067	9,175	9,830	N/A
6/30/2019	23,562	7,958	9,070	9,726	N/A
3/31/2019	23,750	8,075	9,715	10,414	N/A
12/31/2018	23,747	8,394	10,558	11,296	N/A
9/30/2018	23,319	2,202	10,448	11,114	N/A
6/30/2018	23,188	2,364	10,642	11,295	N/A
3/31/2018	22,939	2,219	10,868	11,519	N/A
12/31/2017	22,849	1,979	N/A	11,177	N/A
9/30/2017	23,012	8,178	N/A	11,265	N/A
6/30/2017	23,050	8,174	N/A	10,473	N/A
3/31/2017	22,928	7,893	N/A	10,824	N/A
12/31/2016	22,991	7,722	N/A	10,354	N/A
9/30/2016	22,562	7,587	N/A	9,327	N/A
6/30/2016	22,474	7,433	N/A	9,557	N/A
3/31/2016	22,156	7,216	N/A	10,164	N/A
12/31/2015	21,662	6,939	N/A	9,731	N/A
9/30/2015	21,457	6,433	N/A	10,103	N/A
6/30/2015	20,765	5,814	N/A	9,952	N/A
3/31/2015	20,575	5,708	N/A	8,895	N/A
12/31/2014	20,063	5,158	N/A	8,952	N/A
9/30/2014	19,743	4,885	N/A	7,945	N/A
6/30/2014	19,460	5,009	N/A	7,011	N/A
3/31/2014	18,959	4,720	N/A	6,384	N/A
12/31/2013	18,676	5,081	N/A	6,291	N/A
9/30/2013	17,980	4,848	N/A	5,268	N/A
6/30/2013	17,551	4,587	N/A	5,184	N/A

アナリストによる今後の成長予測

収入対貯蓄率: AMGNの予測収益成長率 (年間18.2% ) は貯蓄率 ( 2.4% ) を上回っています。

収益対市場: AMGNの収益 ( 18.2% ) はUS市場 ( 14.8% ) よりも速いペースで成長すると予測されています。

高成長収益: AMGNの収益は増加すると予測されていますが、大幅には増加しません。

収益対市場: AMGNの収益 ( 3.3% ) US市場 ( 8.7% ) よりも低い成長が予測されています。

高い収益成長: AMGNの収益 ( 3.3% ) 20%よりも低い成長が予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: AMGNの自己資本利益率は、3年後には非常に高くなると予測されています ( 191 %)。

Amgen 将来の成長

Future 基準チェック /36

主要情報

今後の成長に関する最新情報

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Consensus EPS estimates fall by 20%

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Recent updates

Amgen: You Haven't Seen Anything Yet

Amgen Inc. Announces U.S. Food and Drug Administration Approves Blincyto

Amgen Announces Positive Results for Phase 3 Registrational Trial Evaluating Uplizna® (Inebilizumab-Cdon) for Treatment of Immunoglobulin G4-Related Disease (Igg4-Rd)

Amgen Is A Fantastic Dividend Growth Stock With A Weight-Loss Wild Card

Amgen Stock: Poised To Break Out (Technical Analysis)

New minor risk - Earnings quality

FDA Approves Amgen's IMDELLTRA™? (Tarlatamab-Llle) for the Treatment of Adult Patients with Extensive-Stage Small Cell Lung Cancer

Insider recently sold US$663k worth of stock

Upcoming dividend of US$2.25 per share

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 41% Discount?

New minor risk - Profit margin trend

First quarter 2024 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Stock: Recent Weakness Is Not A Buying Opportunity Yet

Amgen Inc. to Report Q1, 2024 Results on May 02, 2024

Amgen to Submits Marketing Authorization Application to the European Medicines Agency

Amgen Inc., Annual General Meeting, May 31, 2024

Amgen: The Giant With An Impressive Pipeline

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Move Over Eli Lilly: Amgen Could Be The Next Obesity Wonder Stock

Amgen Will Benefit From Increased Medical Spending

Dividend of US$2.25 announced

Amgen Presents New Research on Otezla (Apremilast) at AAD 2024

Amgen Announces 2024 Second Quarter Dividend, Payable on June 7,2024

Amgen: A Good Dividend Growth Stock For The Watch List

Amgen's (NASDAQ:AMGN) Shareholders May Want To Dig Deeper Than Statutory Profit

Pinning Down Amgen Inc.'s (NASDAQ:AMGN) P/E Is Difficult Right Now

Consensus EPS estimates fall by 20%

Amgen: Weight Loss Drug Candidate Debate A Red Herring - Buying The Dip Advisable

New minor risk - Earnings quality

Upcoming dividend of US$2.25 per share at 3.0% yield

Full year 2023 earnings: EPS misses analyst expectations

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2024

Amgen Inc. to Report Q4, 2023 Results on Feb 06, 2024

Amgen: Accelerating The Business And Dividend Growth

Is Amgen Inc. (NASDAQ:AMGN) Trading At A 44% Discount?

Up 40%, 3%-Yielding Amgen Is Still One Of My Favorite Healthcare Stocks

Is Amgen (NASDAQ:AMGN) A Risky Investment?

Amgen Provides Regulatory Update on Status of LUMAKRAS (Sotorasib)

Amgen Inc. Announces Executive Changes

Here's Why Amgen (NASDAQ:AMGN) Has Caught The Eye Of Investors

Executive VP recently sold US$2.7m worth of stock

Executive VP notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.1% yield

Amgen Presents New Data from Phase 2 Trial of Dazodalibep in Sjogren's Syndrome at ACR 2023

Amgen Inc. Presents New Data That Show Blood Pressure Decides for Results Treated with Krystexxa (PegLOTICase)

Amgen Inc. Provides Earnings Guidance for the Full Year 2023

Third quarter 2023 earnings: EPS misses analyst expectations

Amgen Inc. to Report Q3, 2023 Results on Oct 31, 2023

Amgen Inc. Declares Dividend for the Fourth Quarter of 2023, Payable on December 8, 2023

Are Investors Undervaluing Amgen Inc. (NASDAQ:AMGN) By 46%?

Amgen Presents New LUMAKRAS (Sotorasib) Plus Vectibix (Panitumumab) Data in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer

Amgen Inc. to Present New Research from Oncolfolio and Pipeline At ESMO2023

Amgen Inc. (NasdaqGS:AMGN) completed the acquisition of Horizon Therapeutics Public Limited Company (NasdaqGS:HZNP).

Is Amgen (NASDAQ:AMGN) Using Too Much Debt?

Amgen Presents New Lumakras® (Sotorasib) Plus Chemotherapy Data in First-Line Kras G12c Nsclc At Wclc

Do Amgen's (NASDAQ:AMGN) Earnings Warrant Your Attention?

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen and Horizon Therapeutics plc Resolve FTC Lawsuit, Clearing Path to Close Acquisition

Amgen Presents Phase 2 OLPASIRan Data at ESC 2023

Amgen Announces to Discuss Application for LUMAKRAS (Sotorasib) for Treatment of KRAS G12C-Positive NSCLC at FDA Advisory Committee Meeting

Insider recently sold US$2.5m worth of stock

Insider notifies of intention to sell stock

Upcoming dividend of US$2.13 per share at 3.3% yield

Amgen Inc. Announces Management Changes

Amgen (NASDAQ:AMGN) Is Increasing Its Dividend To $2.13

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Amgen Inc. Provides Earnings Guidance for the Year Ending December 31, 2023

Amgen Inc. to Report Q2, 2023 Results on Aug 03, 2023

Amgen Inc. Announces U.S. Food and Drug Administration Approves Supplemental Biologics License Application for BLINCYTO